02348 DAWNRAYS PHARMA
- 1.190
- +0.020+1.71%
DAWNRAYS PHARMA News
東瑞製葯：2023 年報
DAWNRAYS PHARMA To Go Ex-Dividend On May 28th, 2024 With 0.065 HKD Dividend Per Share
March 25th - $DAWNRAYS PHARMA(02348.HK)$ is trading ex-dividend on May 28th, 2024. Shareholders of record on May 29th, 2024 will receive 0.065 HKD dividend per share on June 12th, 2024. The ex-div
Dawnrays' 2023 Profit Falls 9% on Lower Revenue
Dawnrays Pharmaceutical's (HKG:2348) attribrtuable profit fell 9% to 326 million yuan, or 0.2174 yuan per share, in 2023, from 358.1 million yuan, or 0.2389 yuan per share, in 2022, according to a Friday filing with the Hong Kong bourse.
Changes in Hong Kong stocks | Dongrui Manufacturing (02348) fell by more than 10%. Profit attributable to shareholders of $326 million in 2023 decreased by 8.95% year-on-year
Dongrui Manufacturing (02348) fell by more than 10%, down 12.88% at press time, to HK$1.15, with a turnover of HK$1.54 million.
Dongrui Pharmaceuticals (02348) will pay a final dividend of HK6.5 cents per share on June 12
Dongrui Pharmaceuticals (02348) announced that it will pay a final dividend of HK6.5 cents per share on June 12, 2024.
The annual profit attributable to owners of Dongrui Pharmaceuticals (02348.HK) was about 326 million yuan, a year-on-year decrease of about 9.0%
Gelonghui, March 22丨Dongrui Pharmaceutical (02348.HK) announced that for the year ended December 31, 2023, the company recorded revenue of about RMB 1.15 billion, a year-on-year decrease of about 9.9%. Profit attributable to owners of parent companies was approximately RMB 326 million, a year-on-year decrease of approximately 9.0%. The Board recommended a year-end dividend of HK$0.065 per share.
DAWNRAYS PHARMA: ANNOUNCEMENT OF THE ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Dongrui Pharmaceuticals (02348.HK) plans to hold a board meeting on March 22 to approve annual results
Gelonghui, March 8, 丨 Dongrui Pharmaceutical (02348.HK) issued an announcement. The company's board of directors meeting will be held on March 22, 2024 (Friday) to approve (among other things) the publication of the annual results announcements of the company and its subsidiaries for the year ended December 31, 2023, and to consider the proposed payment of a final dividend (if any).
DAWNRAYS PHARMA: DATE OF BOARD MEETING
Akeso Unit Buys 35% Stake in Biopharmaceutical Firm From Dawnrays; Akeso Shares Slide 3%
Akeso (HKG:9926) unit Akeso Biopharma agreed to purchase a 35% stake in AD Pharmaceuticals from Dawnrays Pharmaceutical (HKG:2348) unit Dawnrays Biotechnology Capital (Asia) for 267.4 million yuan, a
[Hong Kong Stock Connect] Kangfang Biotech (09926) buys 35% of Kangrong Oriental's shares involving RMB 267 million
Jinwu Financial News | An indirect wholly-owned subsidiary of Kangfang Biotech (09926) purchased 35% of Kangrong Oriental's shares. After completing the acquisition, Kangrong Oriental will become an indirect wholly-owned subsidiary of the company. The cost was RMB 267 million. Kangrong Oriental is an innovative biopharmaceutical company integrating the development, production and sale of antibody drugs. It was established in a joint venture in December 2016 in the form of technology and product injection by the buyer and capital injection by the seller. Kangrong Oriental closely follows the cutting edge of scientific development and focuses on the innovative development of innovative drugs and combination therapies for major diseases such as cardiovascular and oncology.
Dongrui Pharmaceuticals (02348) plans to sell 35% of Kangrong Dongfang's shares
Dongrui Pharmaceuticals (02348) issued an announcement. On February 8, 2024, Dongrui Biotech, a wholly-owned subsidiary of the company, and...
Dawnrays Pharmaceutical to Sell Entire 35% Stake in AD Pharmaceuticals for CNY267.39M
Dawnrays Pharmaceutical to Sell Entire 35% Stake in AD Pharmaceuticals for CNY267.39M
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Pioneer Securities Pharmaceutical's 24-year Strategy: Risks have been fully released, and subsequent industry valuations are expected to rise steadily
The Zhitong Finance App learned that Pioneer Securities released a research report saying that due to more scientific collection rules, after the collection gradually covered a large stock of generic drugs/high-value consumables, the performance was clear, and new performance growth points were formed after innovative products were launched one after another, and the drugs/device-related companies in the hospital will usher in a new growth cycle after their performance stabilizes.
Guotai Junan: The pharmaceutical industry has a low market risk appetite and selects “cost-effective” stocks with steady management
Guotai Junan released a research report saying that the high base effect in COVID-related fields dissipated throughout the year, and the growth rate is expected to gradually return to its own path, but Q1, especially in January-February, was still affected by the base effect of the epidemic.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
CITIC Construction Investment: The innovative drug sector has reached the bottom of the valuation to seize multi-line opportunities and focus on systematized pharmaceutical companies entering the harvest period
CITIC Construction Investment released a research report saying that the innovative pharmaceutical industry is expected to achieve good growth in 2024, and is optimistic about the sector's performance.
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Analysis
Price Target
No Data
